Accounting for Common Stock of OncoCyte, at Fair Value (Details Narrative) - OncoCyte Corporation [Member] - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Investment owned, balance, shares	1,100,000		1,100,000		3,600,000
Investment Owned, at Fair Value	$ 6.4		$ 6.4		$ 8.7
Closing price per share	$ 5.74		$ 5.74		$ 2.39
Unrealized loss on marketable equity securities	$ 0.6	$ 4.0	$ 1.8	$ 4.2
Equity Method Investment, Realized Gain (Loss) on Disposal		$ 2.1	$ 6.0	$ 3.1